[go: up one dir, main page]

WO2012048013A3 - Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales - Google Patents

Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales Download PDF

Info

Publication number
WO2012048013A3
WO2012048013A3 PCT/US2011/054945 US2011054945W WO2012048013A3 WO 2012048013 A3 WO2012048013 A3 WO 2012048013A3 US 2011054945 W US2011054945 W US 2011054945W WO 2012048013 A3 WO2012048013 A3 WO 2012048013A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
nucleoside compounds
guanosine nucleoside
viral injections
phosphorodiamidate derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/054945
Other languages
English (en)
Other versions
WO2012048013A2 (fr
Inventor
Christopher Mcguigan
Mohamed ALJARAH
Karolina MADELA
Claire Bourdin
Sarah Jones
Stanley Chamberlain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Inhibitex Inc
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University, Inhibitex Inc filed Critical University College Cardiff Consultants Ltd
Publication of WO2012048013A2 publication Critical patent/WO2012048013A2/fr
Publication of WO2012048013A3 publication Critical patent/WO2012048013A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (I) ayant une structure utile dans le traitement d'infections virales chez les mammifères induites, au moins en partie, par un virus de la famille de virus des Flaviviridae. L'invention concerne également des procédés de traitement d'infections virales par le biais de l'administration de ces composés.
PCT/US2011/054945 2010-10-06 2011-10-05 Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales Ceased WO2012048013A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39035710P 2010-10-06 2010-10-06
US61/390,357 2010-10-06

Publications (2)

Publication Number Publication Date
WO2012048013A2 WO2012048013A2 (fr) 2012-04-12
WO2012048013A3 true WO2012048013A3 (fr) 2012-06-14

Family

ID=45928409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054945 Ceased WO2012048013A2 (fr) 2010-10-06 2011-10-05 Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales

Country Status (1)

Country Link
WO (1) WO2012048013A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
PT3447061T (pt) 2011-03-01 2021-12-23 NuCana plc Formulação farmacêutica que compreende um derivado de fosforamidato de 5-fluoro-2¿-desoxiuridina para utilização no tratamento de cancro
WO2012154321A1 (fr) * 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Composés et compositions pharmaceutiques pour le traitement d'infections virales
EP2755983B1 (fr) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
HK1200835A1 (en) 2011-12-20 2015-08-14 Riboscience Llc 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
SG11201407674TA (en) * 2012-05-22 2014-12-30 Idenix Pharmaceuticals Inc D-amino acid compounds for liver disease
EP2852604B1 (fr) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
EP2852605B1 (fr) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
KR20150027155A (ko) 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 바이러스 감염의 치료를 위한 뉴클레오시드 화합물의 부분입체이성질체적으로 풍부한 포스포르아미데이트 유도체의 제조 방법
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
EP2909222B1 (fr) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC Nucléosides 2', 4'-pontés pour l'infection par le vhc
WO2014099941A1 (fr) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
WO2014137926A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2970357B1 (fr) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
EP2996696A4 (fr) 2013-05-16 2016-12-21 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
WO2014197578A1 (fr) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
WO2015017713A1 (fr) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP4088725A1 (fr) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. Nucléotides de purine substitués en position 2'-n6 pour le traitement du picornaviridae
HRP20250266T1 (hr) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4355319A4 (fr) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. Polythérapie anti-vhc avantageuse

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138797A1 (en) * 2001-06-29 2003-07-24 Micrologix Biotech Inc. Nucleic acid-based compounds
US20080009461A1 (en) * 2006-06-27 2008-01-10 Biovitrum Ab Therapeutic compounds
US20080286230A1 (en) * 2006-12-28 2008-11-20 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010075517A2 (fr) * 2008-12-23 2010-07-01 Pharmasset, Inc. Analogues de nucléoside
WO2010081082A2 (fr) * 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
US20100233120A1 (en) * 2006-08-11 2010-09-16 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20100249056A1 (en) * 2006-05-03 2010-09-30 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138797A1 (en) * 2001-06-29 2003-07-24 Micrologix Biotech Inc. Nucleic acid-based compounds
US20100249056A1 (en) * 2006-05-03 2010-09-30 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
US20080009461A1 (en) * 2006-06-27 2008-01-10 Biovitrum Ab Therapeutic compounds
US20100233120A1 (en) * 2006-08-11 2010-09-16 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20080286230A1 (en) * 2006-12-28 2008-11-20 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010075517A2 (fr) * 2008-12-23 2010-07-01 Pharmasset, Inc. Analogues de nucléoside
WO2010081082A2 (fr) * 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
US20100298257A1 (en) * 2009-05-20 2010-11-25 Pharmasset, Inc. Nucleoside phosphoramidates

Also Published As

Publication number Publication date
WO2012048013A2 (fr) 2012-04-12

Similar Documents

Publication Publication Date Title
WO2012048013A3 (fr) Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales
WO2012092484A3 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
WO2010081082A3 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
MD20140135A2 (ro) Inhibitori macrociclici ai viruşilor din familia Flaviviridae
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
WO2013040492A3 (fr) Procédés permettant de traiter le virus de l'hépatite c (hcv)
NZ748966A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
NZ603310A (en) Heterocyclic flaviviridae virus inhibitors
UA116083C2 (uk) Похідні пурину для лікування вірусних інфекцій
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
MX2012008221A (es) Inhibidores de virus flaviviridae.
NZ600817A (en) Inhibitors of flaviviridae viruses
EA201390538A1 (ru) Противовирусные соединения
PL2888241T3 (pl) 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
EA201490015A1 (ru) Композиции на основе дрожжей и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта
IN2012DN01855A (fr)
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
IN2014MN01548A (fr)
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EA201000051A1 (ru) Противовирусные соединения, композиции и способы использования

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831528

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11831528

Country of ref document: EP

Kind code of ref document: A2